OR51B5 Antibody

What is OR51B5 and why is it significant for research applications?

OR51B5 (Olfactory Receptor Family 51 Subfamily B Member 5) is a G protein-coupled receptor initially identified in olfactory tissue but now known to be expressed in various non-olfactory tissues including lung epithelium and leukemia cells . Its significance lies in its diverse roles beyond olfaction:

• In lung epithelial cells, OR51B5 activation may be involved in airway-sensitivity to odorants and non-type 2 inflammation pathways

• In leukemia cells (K562 and acute myelogenous leukemia), OR51B5 activation inhibits cancer cell proliferation via reduction in p38-MAPK phosphorylation

• Expression in multiple cancer types makes it a potential biomarker and therapeutic target

Researchers should consider OR51B5's tissue-specific functions when selecting antibodies for particular experimental contexts.

What validation methods should be employed before using OR51B5 antibodies?

Before implementing OR51B5 antibodies in experiments, comprehensive validation is essential:

• Genetic validation: Compare antibody signal in wild-type versus OR51B5 knockdown/knockout samples

• Peptide competition assay: Pre-incubate antibody with the immunizing peptide to verify specific binding (as demonstrated with LOVO cells)

• Cross-reactivity assessment: Test reactivity against closely related olfactory receptors

• Multi-technique validation: Confirm detection across multiple methods (RT-PCR, Western blot, immunocytochemistry) as demonstrated in studies with K562 cells

• Expression pattern comparison: Compare with published OR51B5 mRNA expression data

These validation steps are critical as olfactory receptors share sequence similarities that can confound antibody specificity.

How do available OR51B5 antibodies differ in their binding epitopes and applications?

Commercial OR51B5 antibodies target different epitopes, affecting their utility in specific applications:

When selecting an antibody, consider the experimental context: C-terminal antibodies may be less effective if the receptor undergoes C-terminal processing, while antibodies targeting internal domains may detect both mature and precursor forms of the protein.

What are the optimal protocols for detecting OR51B5 in different cell and tissue types?

Protocol optimization differs by cell/tissue type due to varying expression levels and subcellular localization:

For Leukemia Cells (K562, AML blood samples):

• Western blot: Lysis in RIPA buffer containing protease inhibitors; 30-50μg protein loading; 1:500 dilution of primary antibody

• Immunocytochemistry: 4% PFA fixation, 0.1% Triton X-100 permeabilization, 5% goat serum blocking, 1:100 primary antibody dilution (overnight at 4°C)

For Lung Epithelial Cells (A549, ALI-PBECs):

• Use of air-liquid interface cultures for primary bronchial epithelial cells enhances physiological relevance

• Western blot: TBST with 5% non-fat milk blocking, 1:500 antibody dilution

• Immunofluorescence: Special attention to permeabilization steps as OR51B5 shows preferential intracellular localization in these cells

For all systems, detection sensitivity can be enhanced by using signal amplification methods such as HRP-conjugated secondary antibodies with ECL Plus detection systems.

How can researchers differentiate between membrane-bound and intracellular OR51B5 pools?

OR51B5 shows "preferential intracellular localization" in lung epithelial cells , requiring specific approaches to distinguish receptor pools:

• Fractionation approach:

  • Separate membrane and cytosolic fractions using differential centrifugation

  • Confirm fraction purity with markers (E-cadherin for membrane )

  • Analyze OR51B5 distribution by Western blot in each fraction

• Immunofluorescence co-localization:

  • Double-stain with OR51B5 antibody and compartment markers

  • Use membrane markers (E-cadherin) and intracellular organelle markers

  • Analyze using confocal microscopy with z-stack imaging

  • Calculate colocalization coefficients (Pearson's, Mander's)

• Surface biotinylation:

  • Label surface proteins with membrane-impermeable biotin reagents

  • Isolate biotinylated proteins with streptavidin pulldown

  • Compare OR51B5 levels in biotinylated (surface) versus non-biotinylated (internal) fractions

These approaches can reveal whether OR51B5 trafficking and localization change upon ligand exposure or in disease states.

What controls are essential when using OR51B5 antibodies in experimental settings?

Robust controls are critical for interpreting OR51B5 antibody data:

Essential Controls:

• Peptide competition: Pre-incubate antibody with immunizing peptide to validate signal specificity (demonstrated with LOVO cells)

• Negative tissue control: Use tissues known not to express OR51B5 or OR51B5-knockout samples

• Positive control: Include validated OR51B5-expressing samples (K562 cells or transfected HEK293 cells)

• Loading controls: Use housekeeping proteins like GAPDH or β-actin for Western blot normalization

• Isotype control: Use matched IgG concentration for immunostaining experiments

• Reverse transcriptase negative (-RT) control: When confirming expression by RT-PCR to exclude genomic DNA contamination

Application-Specific Controls:

• For siRNA experiments targeting OR51B5, include scrambled siRNA controls

• For receptor activation studies, include both agonist (isononyl alcohol, farnesol) and vehicle controls

How can OR51B5 antibodies be used to study receptor-mediated signaling pathways?

OR51B5 antibodies can be powerful tools for dissecting signaling mechanisms when combined with other techniques:

Integrated Signaling Analysis Approach:

• Receptor activation monitoring:

  • Use calcium imaging to measure intracellular Ca²⁺ following OR51B5 activation by ligands (farnesol, isononyl alcohol)

  • Combine with OR51B5 immunostaining to correlate expression with response magnitude

• Downstream signaling analysis:

  • Western blotting for phosphorylated signaling proteins (p38-MAPK, CREB) following receptor activation

  • In K562 cells, OR51B5 activation reduces p38-MAPK phosphorylation, correlating with decreased proliferation

• Pathway dissection:

  • Use Western blot with OR51B5 antibodies in combination with pathway inhibitors:

    • Adenylate cyclase inhibitors (SQ22536)

    • PLC inhibitors

    • L-type and T-type calcium channel blockers

This integrated approach has revealed that OR51B5 signaling involves both cAMP and PLC pathways in different cell types, demonstrating context-dependent signaling mechanisms.

How can researchers resolve contradictory data when using different OR51B5 antibodies?

When faced with discrepant results from different OR51B5 antibodies, implement a systematic troubleshooting approach:

• Epitope mapping comparison:

  • Compare the epitopes recognized by different antibodies

  • Antibodies targeting different regions may yield different results if:

    • Post-translational modifications mask epitopes

    • Protein interactions obscure binding sites

    • Protein conformation affects epitope accessibility

• Cross-validation strategy:

  • Validate protein detection using multiple antibodies in parallel

  • Implement genetic approaches (siRNA, CRISPR) to confirm specificity

• Functional validation:

  • Correlate antibody detection with functional responses to known OR51B5 ligands

  • Compare calcium responses to isononyl alcohol or farnesol with antibody signal intensity

This multi-faceted approach can determine which antibody provides the most reliable data for specific experimental contexts.

What approaches can researchers use to study OR51B5 regulation at the transcriptional level?

Recent research has identified TBX6 as a key transcriptional regulator of OR51B5 , suggesting methodologies to study its regulation:

• Promoter analysis techniques:

  • Luciferase reporter assays using the OR51B5 core promoter region (-153 to -111 bp)

  • Site-directed mutagenesis of TBX6 binding sites in the promoter

• Expression regulation assessment:

  • Overexpression or knockdown of TBX6 to evaluate effects on OR51B5 expression

  • qPCR and Western blot to measure resultant changes in OR51B5 mRNA and protein

  • Correlation analysis between TBX6 and OR51B5 expression in various tissues and disease states

• Epigenetic regulation:

  • DNA methylation analysis of the OR51B5 promoter region

  • Histone modification profiling (H3K4me3, H3K27ac) at the OR51B5 locus

  • Effect of HDAC inhibitors on OR51B5 expression

These approaches can reveal how OR51B5 expression is dynamically regulated in different cellular contexts, potentially explaining its varied expression across normal and pathological tissues.

How can researchers integrate OR51B5 antibody data with functional studies in disease models?

To establish clinical and physiological relevance of OR51B5 expression patterns, researchers should integrate antibody-based detection with functional readouts:

For Leukemia Research:

• Correlate OR51B5 protein levels (Western blot, immunohistochemistry) with:

  • Patient clinical parameters (remission rates, survival)

  • Response to isononyl alcohol treatment in patient-derived samples

  • Changes in proliferation markers (Ki-67, BrdU incorporation)

  • Alterations in p38-MAPK phosphorylation status

For Respiratory Research:

• In lung epithelial models:

  • Measure OR51B5 levels in asthma vs. normal samples

  • Correlate receptor expression with inflammatory cytokine production (IL-6, IL-8)

  • Assess receptor regulation during exposure to odorants/irritants

  • Evaluate potential for receptor antagonism as a therapeutic approach for non-type 2 inflammation asthma

• Mechanistic investigations:

  • siRNA knockdown of OR51B5 to assess impact on odorant-induced inflammation

  • Pharmacological blockade using selective antagonists (when identified)

  • OR51B5 overexpression to determine if receptor levels correlate with sensitivity to odorants

This integrated approach connects molecular findings with physiological outcomes, enhancing translational relevance of OR51B5 research.

What are common pitfalls when working with OR51B5 antibodies and how can they be addressed?

Several technical challenges can arise when working with OR51B5 antibodies:

For intracellular OR51B5 detection, special attention to permeabilization is critical as this receptor shows "preferential intracellular localization" in some cell types .

How can researchers ensure reproducibility when using OR51B5 antibodies across different experiments?

Ensuring reproducibility requires rigorous standardization:

• Standard operating procedures (SOPs):

  • Maintain detailed protocols for sample preparation and antibody usage

  • Document key parameters:

    • Fixation method and duration (4% PFA, 20 min, 4°C)

    • Blocking solution composition (5% goat serum in PBST)

    • Antibody dilutions (1:100-1:500 for immunostaining)

    • Incubation conditions (overnight at 4°C)

• Antibody validation and management:

  • Create internal reference standards for validation

  • Document antibody lot numbers and maintain lot consistency

  • Prepare aliquots to minimize freeze-thaw cycles

  • Store according to manufacturer recommendations (-20°C long-term, 4°C short-term)

• Quantification standardization:

  • Use digital image analysis with standardized parameters

  • Include calibration standards in Western blots

  • Implement blinded analysis when possible

  • Use consistent normalization methods

Maintaining detailed laboratory notebooks with these parameters facilitates troubleshooting when reproducibility issues arise.

What emerging technologies can enhance OR51B5 detection sensitivity and specificity?

Advanced technologies offer improved detection capabilities:

• Proximity ligation assay (PLA):

  • Enables detection of protein-protein interactions involving OR51B5

  • Useful for studying interactions with downstream signaling molecules

  • Provides single-molecule resolution in intact cells

• Super-resolution microscopy:

  • Structured illumination microscopy (SIM)

  • Stimulated emission depletion microscopy (STED)

  • Photoactivated localization microscopy (PALM)

  • These techniques provide subcellular localization details beyond conventional confocal microscopy

• Mass spectrometry-based proteomics:

  • Targeted proteomics using parallel reaction monitoring

  • Validation of antibody specificity by identifying peptides recognized

  • Quantification of OR51B5 expression levels independent of antibodies

• CRISPR-based tagging:

  • Endogenous tagging of OR51B5 with fluorescent proteins or epitope tags

  • Provides live-cell imaging capabilities

  • Reduces reliance on antibody specificity

These emerging technologies complement traditional antibody-based approaches and can resolve contradictory findings from conventional methods.

How might OR51B5 antibodies contribute to therapeutic development for leukemia and respiratory conditions?

OR51B5 antibodies can facilitate drug discovery and therapeutic development through several approaches:

For Leukemia Therapeutics:

• Target validation: OR51B5 activation by isononyl alcohol reduces K562 cell proliferation

• Screening workflows:

  • Use OR51B5 antibodies to monitor receptor expression in patient samples

  • Develop high-throughput screenings for novel OR51B5 ligands with higher affinity than isononyl alcohol

  • Assess downstream p38-MAPK phosphorylation as a pharmacodynamic marker

For Respiratory Disease Therapeutics:

• Antagonist development:

  • OR51B5 antagonism may represent a "promising strategy in treatment of odorant-induced asthma with non-type 2 inflammation"

  • Antibodies can validate target engagement in preclinical models

  • Monitor OR51B5 expression changes during disease progression and treatment

• Personalized medicine approaches:

  • OR51B5 antibodies can help stratify patients based on receptor expression levels

  • Identify patient subgroups most likely to benefit from OR51B5-targeted therapies

For both therapeutic areas, antibodies with high specificity will be crucial for translational research from bench to bedside.

What knowledge gaps remain in OR51B5 research that specialized antibodies could address?

Several critical knowledge gaps could be addressed with specialized OR51B5 antibodies:

• Receptor dynamics and trafficking:

  • Phospho-specific antibodies to detect regulatory post-translational modifications

  • Conformation-specific antibodies to distinguish active vs. inactive receptor states

  • Antibodies recognizing different glycosylation states to study maturation

• Tissue-specific expression patterns:

  • Comprehensive immunohistochemical mapping across healthy and disease tissues

  • Correlation with functional responses to identify tissues where OR51B5 signaling is physiologically relevant

  • Identification of previously unknown sites of expression

• Species-specific conservation and differences:

  • Cross-species reactive antibodies to enable translational research

  • Species-specific antibodies to identify unique regulatory mechanisms

  • Evolutionary conservation analysis of OR51B5 functions

• Splice variant detection:

  • Isoform-specific antibodies to distinguish potential OR51B5 variants

  • Correlation of splice variant expression with functional outcomes